These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12380159)

  • 1. [Caution in therapy of ventricular extrasystole. Staying safe with electrolytes].
    MMW Fortschr Med; 2002 Aug; 144(33-34):62. PubMed ID: 12380159
    [No Abstract]   [Full Text] [Related]  

  • 2. Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators.
    Akiyama T; Pawitan Y; Greenberg H; Kuo CS; Reynolds-Haertle RA
    Am J Cardiol; 1991 Dec; 68(17):1551-5. PubMed ID: 1720917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST).
    Anderson JL; Platia EV; Hallstrom A; Henthorn RW; Buckingham TA; Carlson MD; Carson PE
    Circulation; 1994 Dec; 90(6):2843-52. PubMed ID: 7994829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
    Cardiac Arrhythmia Suppression Trial (CAST) Investigators
    N Engl J Med; 1989 Aug; 321(6):406-12. PubMed ID: 2473403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Postinfarct ventricular extrasystole and the use of anti-arrhythmic drugs: a danger anticipated by electrophysiologists].
    Farré J; Brugada P
    Rev Esp Cardiol; 1989 Oct; 42(8):498-500. PubMed ID: 2481326
    [No Abstract]   [Full Text] [Related]  

  • 6. The Cardiac Arrhythmia Suppression Trial: Implications for nursing practice.
    Kellen JC; Ettinger A; Todd L; Brezsnyak ML; Campion J; McBride R; Thomas S; Corum J; Schron E
    Am J Crit Care; 1996 Jan; 5(1):19-25. PubMed ID: 8680488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The spectrum of CAST I and II.
    Somberg J
    J Clin Pharmacol; 1991 Nov; 31(11):1041. PubMed ID: 1721629
    [No Abstract]   [Full Text] [Related]  

  • 8. Crime, misdemeanor, and arrhythmia decoding CAST.
    Kerin NZ
    J Clin Pharmacol; 1991 Nov; 31(11):1044-52. PubMed ID: 1753008
    [No Abstract]   [Full Text] [Related]  

  • 9. Predicting mortality after myocardial infarction from the response of RR variability to antiarrhythmic drug therapy.
    Bigger JT; Rolnitzky LM; Steinman RC; Fleiss JL
    J Am Coll Cardiol; 1994 Mar; 23(3):733-40. PubMed ID: 7509355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of ventricular arrhythmias after CAST.
    Tonkin AM
    Med J Aust; 1992 Apr; 156(7):488-92. PubMed ID: 1372950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST).
    Epstein AE; Hallstrom AP; Rogers WJ; Liebson PR; Seals AA; Anderson JL; Cohen JD; Capone RJ; Wyse DG
    JAMA; 1993 Nov; 270(20):2451-5. PubMed ID: 8230622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I.
    Greenberg HM; Dwyer EM; Hochman JS; Steinberg JS; Echt DS; Peters RW
    Br Heart J; 1995 Dec; 74(6):631-5. PubMed ID: 8541168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An interim perspective on the removal of encainide and flecainide from the cardiac arrhythmia suppression trial.
    Coyle JD; Schaal SF
    DICP; 1989 Jun; 23(6):478-9. PubMed ID: 2500783
    [No Abstract]   [Full Text] [Related]  

  • 14. CAST and beyond. Implications of the Cardiac Arrhythmia Suppression Trial. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.
    Akhtar M; Breithardt G; Camm AJ; Coumel P; Janse MJ; Lazzara R; Myerburg RJ; Schwartz PJ; Waldo AL; Wellens HJ
    Circulation; 1990 Mar; 81(3):1123-7. PubMed ID: 1689621
    [No Abstract]   [Full Text] [Related]  

  • 15. Fact and fiction--results of the cardiac arrhythmia suppression trial.
    Wyse DG
    Can J Cardiol; 1991; 7(1):51-4; discussion 55-8. PubMed ID: 1902755
    [No Abstract]   [Full Text] [Related]  

  • 16. Time to arrhythmic, ischemic, and heart failure events: exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Suppression Trial.
    Hallstrom AP; Anderson JL; Carlson M; Davies R; Greene HL; Kammerling JM; Romhilt DW; Duff HJ; Huther M
    Am Heart J; 1995 Jul; 130(1):71-9. PubMed ID: 7611126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Non-invasive evaluation of the effectiveness of flecainide in the treatment of ventricular extrasystole arrhythmia].
    Mangini SG; Mastropasqua F; Lagioia R; Ricci A; Scrutinio D; Rizzon P
    Cardiologia; 1986 Jun; 31(6):443-51. PubMed ID: 2434229
    [No Abstract]   [Full Text] [Related]  

  • 18. Flecainide and CAST.
    Lancet; 1989 Aug; 2(8661):481-2. PubMed ID: 2570188
    [No Abstract]   [Full Text] [Related]  

  • 19. The cardiac arrhythmia suppression trial (CAST).
    Ruskin JN
    N Engl J Med; 1989 Aug; 321(6):386-8. PubMed ID: 2501683
    [No Abstract]   [Full Text] [Related]  

  • 20. [Value of K+ and Mg2+ in treatment of acute myocardial infarct].
    Kunert M; Scheuble L; Stolzenburg H; Gülker H
    Herz; 1997 Jun; 22 Suppl 1():63-72. PubMed ID: 9333594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.